Processed Orange and the Glycemic Response

Inclusion Criteria: * Males (due to potential hormonal fluctuations in female subjects) aged 30-65 y * BMI: 25-29.9 kg/m2 * Not diabetic \[diagnosed or fasting glucose \>7 mmol/L (126 mg/dL)\] or suffer from other endocrine disorders * Not having suffered a myocardial infarction/stroke in the past 12 mo * Not suffering from renal or bowel disease or have a history of choleostatic liver or pancreatitis * Not on drug treatment for hyperlipidaemia, hypertension, inflammation or hypercoagulation * No history of alcohol misuse * Not planning or on a weight reducing regime * Not taking any fish oil, fatty acid or vitamin and mineral supplements * Non smokers Exclusion Criteria: * Females * Use of medications known to affect lipid metabolism, i.e., hypolipidemic or cholesterol-lowering agents (e.g., Pravastatin, Simuvustatin) * Use of (\>2x/wk) medication for inflammation or hypercoagulation * Anticoagulants (Warfarin) * Inflammation - NSAID's (Tiaprofenic acid, Sulindac, Ibuprofen), Corticosteroids (Betamethasone) * Regular use (\>2x/wk) of any acid-lowering medications, laxatives or anti-diarrheal medications (prescription or over-the-counter \[OTC\]) * Use of medications known or suspected to influence blood pressure, including beta-adrenergic blocking agents (oral or ocular) (e.g., Sotalol, Bisoprolol), beta-adrenergic drugs, calcium channel blocking agents (Amlodipine, Nicardipine), angiotensin converting enzyme (ACE) inhibitors (Captopril, Cilazapril), angiotensin receptor blocking agents (Valsartan), nitrates, diuretics (Chlortalidone), venlafaxine and sibutramine, decongestants or chloroquine * Systolic blood pressure \>150 mmHg and/or diastolic blood pressure \>95 mmHg * CVD including coronary artery disease, left ventricular hypertrophy, congestive heart failure, cerebrovascular disease, stroke, peripheral vascular disease or dysautonomia * Gastrointestinal diseases conditions or medications influencing gastrointestinal absorption including active peptic ulcer disease, treatment with acid-lowering drugs or inflammatory bowel disease * Renal or chronic kidney disease due to any condition, renovascular disease, history of nephrolithiasis or serum creatinine \>1.5 mg/dL * Endocrine disorders including diabetes \[fasting blood glucose \>7 mmol/L (126 mg/dL) or current pharmacologic treatment for diabetes\], untreated thyroid disease, adrenal disease, pheochromocytoma, parathyroid disease or hyperuricemia * Rheumatologic diseases including gout or inflammatory arthritis * Active treatment for cancer of any type (except basal cell carcinoma)\<1 y * Regular use of oral steroids except topical OTC steroids * Regular use of any dietary supplements containing vitamins, minerals, herbal or other plant-based preparations, fish oil supplements (including cod liver oil) or homeopathic remedies. However, subjects who are willing to refrain from the use of these supplements for 1 mo prior to their initial visit (Visit 3) may be considered eligible. * Usual daily ethanol intake of\>2 drinks (24 oz beer, 8 oz wine, 2 oz hard liquor) * Cigarette smoking and/or nicotine replacement use. However, subjects who have stopped using these products for 1 y prior to their initial visit (Visit 1) may be considered eligible. * Illicit drug use * Infrequent (\<3/wk) or excessive (\>3/d) number of regular bowel movements * Specific laboratory blood or urine analysis parameters of: * Creatinine \> 1.5 mg/dL * Electrolytes, calcium, phosphorous - out of normal ranges * ALT and AST \>1.5 nmol * Total bilirubin - above normal range * Triglycerides ≥300 mg/dL * Fasting glucose ≥126 mg/dL * CBC: HCT outside of normal NEL reference ranges at the discretion of the study physician * WBC, PLT - outside of normal NEL reference ranges Strict vegetarians * Those on or planning a weight reducing regime * Unable to consume study meals or products * Subjects with larger than 5 kg weight loss in the last 3 months.